Section Arrow
VERU.NASDAQ
- Veru
Quotes are at least 15-min delayed:2024/05/17 11:29 EDT
Last
 1.3505
-0.0195 (-1.42%)
Day High 
1.39 
Prev. Close
1.37 
1-M High
1.75 
Volume 
332.16K 
Bid
1.35
Ask
1.36
Day Low
1.34 
Open
1.39 
1-M Low
Market Cap 
200.55M 
Currency USD 
P/E -- 
%Yield 5.56 
10-SMA 1.47 
20-SMA 1.4 
50-SMA 1.08 
52-W High 1.92 
52-W Low 0.36 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.35/-0.30
Enterprise Value
213.05M
Balance Sheet
Book Value Per Share
0.31
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
16.30M
Operating Revenue Per Share
0.10
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NBYNovaBay Pharmaceuticals0.1751+0.0551+45.92%-- 
SCPXScorpius Holdings0.11845+0.01835+18.33%-- 
ONCOOnconetix0.1677+0.0267+18.94%-- 
DNAGinkgo Bioworks Holdings0.8157-0.0233-2.78%-- 
JAGXJaguar Health0.2694-0.0173-6.03%-- 
Quotes are at least 15-min delayed:2024/05/17 11:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.